Paxil Class Action
HOME COMMUNICATION CASE SUMMARY LAWYERS
1. A proposed class action has been commenced against GlaxoSmithKline Inc., GlaxoSmithKline plc, Beecham Group plc, SmithKline Beecham plc and SmithKline Beecham Corporation on behalf of all persons in Ontario and elsewhere in Canada who purchased Paxil in Canada during the period from December 4, 1996 to October 9, 2003.
2. The class action concerns an alleged conspiracy which kept generic competition for Paxil from entering the Canadian market, and extended the defendants' market monopoly and exclusive marketing rights for Paxil, for nearly seven years. The action alleges that this allowed the defendants to demand a significantly higher price for Paxil than they could have with generic competition. The plaintiff seeks damages for conspiracy and the right to waive the tort of conspiracy and claim the difference between the price actually charged and received and the price the defendants would have been able to charge in a market with generic competition.
3. If you would like to speak to someone at Sutts, Strosberg LLP about this proposed class action, please call 800.229.5323, extension 8296.
4. To learn more about how a class action works, please click here.
Update: October 31, 2006
IMPORTANT NOTE
This website has been developed to provide general information to potential class members on a class action that has been commenced against GlaxoSmithKline Inc., GlaxoSmithKline plc, Beecham Group plc, SmithKline Beecham plc and SmithKline Beecham Corporation.
The site is not designed to answer questions about your individual situation or entitlement. Do not rely upon the information provided on this website as legal advice in respect of your individual situation nor use it as a substitute for individual legal advice.
The information collected about potential class members will assist counsel in prosecuting the class action and assessing what damages were suffered by the class as a whole. Providing the information requested does not make you the client of Sutts, Strosberg LLP. The court will ultimately decide who will be included as a class member.
This website will be updated from time to time to provide potential class members with information as it becomes available.
HOME COMMUNICATION CASE SUMMARY LAWYERS
1. A proposed class action has been commenced against GlaxoSmithKline Inc., GlaxoSmithKline plc, Beecham Group plc, SmithKline Beecham plc and SmithKline Beecham Corporation on behalf of all persons in Ontario and elsewhere in Canada who purchased Paxil in Canada during the period from December 4, 1996 to October 9, 2003.
2. The class action concerns an alleged conspiracy which kept generic competition for Paxil from entering the Canadian market, and extended the defendants' market monopoly and exclusive marketing rights for Paxil, for nearly seven years. The action alleges that this allowed the defendants to demand a significantly higher price for Paxil than they could have with generic competition. The plaintiff seeks damages for conspiracy and the right to waive the tort of conspiracy and claim the difference between the price actually charged and received and the price the defendants would have been able to charge in a market with generic competition.
3. If you would like to speak to someone at Sutts, Strosberg LLP about this proposed class action, please call 800.229.5323, extension 8296.
4. To learn more about how a class action works, please click here.
Update: October 31, 2006
IMPORTANT NOTE
This website has been developed to provide general information to potential class members on a class action that has been commenced against GlaxoSmithKline Inc., GlaxoSmithKline plc, Beecham Group plc, SmithKline Beecham plc and SmithKline Beecham Corporation.
The site is not designed to answer questions about your individual situation or entitlement. Do not rely upon the information provided on this website as legal advice in respect of your individual situation nor use it as a substitute for individual legal advice.
The information collected about potential class members will assist counsel in prosecuting the class action and assessing what damages were suffered by the class as a whole. Providing the information requested does not make you the client of Sutts, Strosberg LLP. The court will ultimately decide who will be included as a class member.
This website will be updated from time to time to provide potential class members with information as it becomes available.
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON
No comments: